{
  "meta": {
    "title": "05_Antenatal_Screening",
    "url": "https://brainandscalpel.vercel.app/05-antenatal-screening-f189a0ac.html",
    "scrapedAt": "2025-11-30T06:58:06.768Z"
  },
  "questions": [
    {
      "id": 90878,
      "choices": [
        {
          "id": 236380,
          "text": "Repeat measurement of MSAFP at later date"
        },
        {
          "id": 236381,
          "text": "USG"
        },
        {
          "id": 236382,
          "text": "Amniocentesias"
        },
        {
          "id": 236383,
          "text": "Termination of pregnancy"
        }
      ],
      "text": "In pregnancy with increased MSAFP which of the following should be done?",
      "unique_key": "Q5273308",
      "question_audio": null,
      "question_video": null,
      "map_id": 34281513,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) In pregnancy with increased maternal serum AFP, the correct course of action is B) Ultrasound (USG). An elevated maternal serum AFP can be associated with a variety of conditions, including neural tube defects, abdominal wall defects, and multiple gestation. To further investigate the cause of the increased AFP levels, a detailed ultrasound is performed to assess fetal anatomy. USG can help detect structural anomalies such as spina bifida, anencephaly, or gastroschisis, which can be contributing factors to the elevated AFP levels. It also allows the identification of multiple gestations or placental abnormalities, helping to clarify the cause of the elevated AFP. Option A, repeat measurement of maternal serum AFP at a later date, is not a reliable next step. While AFP levels can vary during pregnancy, repeat testing alone will not provide additional diagnostic clarity or rule out any significant conditions. A repeat measurement would delay diagnosis without offering useful information unless a clear cause for the elevation can be determined, which is why it is not typically recommended without further investigation. Option C, amniocentesis, is an invasive procedure used for genetic testing or to assess for specific conditions like neural tube defects or chromosomal abnormalities. However, it is not the first-line approach after an elevated AFP result. The first step should be a non-invasive ultrasound to evaluate fetal anatomy and structure. Amniocentesis might be considered later if specific concerns remain after ultrasound, but it is not routinely performed immediately. Option D, termination of pregnancy, is an extreme response and should not be considered based on an isolated elevated AFP result. Increased AFP does not necessarily indicate a fatal or irreversible condition; it is merely a marker that warrants further investigation. Termination would be considered only if a severe, non-viable fetal condition is confirmed after proper evaluation, which would typically follow a thorough diagnostic process, including ultrasound and possibly amniocentesis.",
      "correct_choice_id": 236381,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44667031697031612/44667031697031612.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/44667031697031612/44667031697031612.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90879,
      "choices": [
        {
          "id": 236384,
          "text": "Amniocentesis"
        },
        {
          "id": 236385,
          "text": "Chorionic villus sampling"
        },
        {
          "id": 236386,
          "text": "Cordocentesis"
        },
        {
          "id": 236387,
          "text": "Noninvasive prenatal testing"
        }
      ],
      "text": "A G3P2,pregnant comes to your clinic at 18 weeks of gestation for genetic counselling .She has a history of two kids born with thalassemia major. Which test would you recommend now?",
      "unique_key": "Q2921367",
      "question_audio": null,
      "question_video": null,
      "map_id": 34470665,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) In this case, the correct response is A) amniocentesis. Since the woman has a history of two children born with thalassemia major, a genetic condition, the risk of the fetus inheriting the same condition is high. Amniocentesis is a diagnostic test that involves sampling amniotic fluid to analyze fetal cells for genetic testing. It is typically performed after 15 weeks of gestation, and it provides a definitive diagnosis of thalassemia major. Given the family history, this test is appropriate for determining whether the current fetus is affected. Option B, chorionic villus sampling (CVS), is also a diagnostic genetic test, but it is typically performed between 10-13 weeks of pregnancy. While CVS provides early results compared to amniocentesis, it carries a slightly higher risk of miscarriage and is not as commonly used later in pregnancy, especially after 15 weeks. Since the woman is already at 18 weeks, amniocentesis would be the more appropriate test. Option C, cordocentesis, is an invasive test where a sample of fetal blood is taken from the umbilical cord. It is typically performed later in pregnancy, usually after 18 weeks, and is used to assess blood conditions such as anemia or infections. However, it is generally considered a second-line test and carries a higher risk of complications compared to amniocentesis, which is the first-line test for genetic analysis in this situation. Option D, non-invasive prenatal testing (NIPT), is a blood test that analyzes fetal DNA circulating in the mother’s blood. While NIPT is useful for detecting common chromosomal abnormalities such as Down syndrome, it does not provide definitive information about thalassemia, a genetic condition not related to chromosomal abnormalities. Therefore, NIPT would not be the best choice for diagnosing thalassemia in this case.",
      "correct_choice_id": 236384,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36941681697031640/36941681697031640.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36941681697031640/36941681697031640.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90880,
      "choices": [
        {
          "id": 236388,
          "text": "Beta hCG and PAPP-A"
        },
        {
          "id": 236389,
          "text": "Unconjugated estradiol and PAPPA"
        },
        {
          "id": 236390,
          "text": "AFP and Inhibin A"
        },
        {
          "id": 236391,
          "text": "AFP and beta hCG"
        }
      ],
      "text": "Which of the following is done for creening of Down's syndrome in first trimester?",
      "unique_key": "Q2140175",
      "question_audio": null,
      "question_video": null,
      "map_id": 34193198,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) hCG and PAPPA. In the first trimester, the screening for Down syndrome typically involves measuring the levels of human chorionic gonadotropin (hCG) and pregnancy-associated plasma protein A (PAPP-A) in maternal blood. Elevated hCG and low PAPP-A levels are associated with an increased risk of Down syndrome. This combination of markers, along with an ultrasound measurement of nuchal translucency (which is not listed in the options but is often used alongside these markers), forms the basis of the first-trimester screening for Down syndrome. First and Second Trimester Screening for Down Syndrome involves a combination of tests to assess the risk of the fetus having chromosomal abnormalities, First trimester screening ening (11–14 Weeks Gestation) 1. Ultrasound (Nuchal Translucency): • Measures the fluid-filled space at the back of the fetal neck. • Increased nuchal translucency (>3 mm) is associated with Down syndrome and other chromosomal abnormalities. 2. Biochemical Markers: • Free Beta-hCG: Elevated levels are associated with Down syndrome. • Pregnancy-Associated Plasma Protein-A (PAPP-A): Low levels are associated with Down syndrome. 3. Combined Screening: • Combines maternal age, nuchal translucency, and biochemical markers. • Detection Rate: ~85-90% for Down syndrome. • False Positive Rate: ~5%. 4. Optional Additions: • Nasal bone assessment (absence or hypoplasia is linked to Down syndrome). • Ductus venosus and tricuspid regurgitation evaluation (abnormal flow patterns may indicate risk). Second Trimester Screening (15–22 Weeks Gestation) 1. Quadruple Test: • Measures four maternal serum markers: • Alpha-Fetoprotein (AFP): Low levels in Down syndrome. • hCG: Elevated levels in Down syndrome. • Unconjugated Estriol (uE3): Reduced levels in Down syndrome. • Inhibin-A: Elevated levels in Down syndrome. • Detection Rate: ~75-80%. • False Positive Rate: ~5%. 2. Ultrasound (Anomaly Scan at 18–20 Weeks): • Looks for “soft markers” like short femur, echogenic bowel, or nuchal fold thickening. • Also checks for major structural abnormalities. Integrated Screening (First + Second Trimester) • Combines first trimester results (PAPP-A, NT) with second trimester markers for a higher detection rate (up to 95%). • Results are reported after second trimester testing. Non-Invasive Prenatal Testing (NIPT): • A highly sensitive option available as early as 9-10 weeks. • Analyzes cell-free fetal DNA in maternal blood. • Detection Rate: ~99% for Down syndrome with a very low false-positive rate.",
      "correct_choice_id": 236388,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54937121697031676/54937121697031676.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54937121697031676/54937121697031676.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90881,
      "choices": [
        {
          "id": 236392,
          "text": "Observation, as no therapy is needed"
        },
        {
          "id": 236393,
          "text": "No therapy needed unless the patient develops symptoms"
        },
        {
          "id": 236394,
          "text": "Initiation of antibiotic therapy"
        },
        {
          "id": 236395,
          "text": "No therapy needed at this time, but antibiotics should be given during labor"
        }
      ],
      "text": "A 19-year-old G2P1 woman at 13 weeks’ gestation comes in for her first prenatal visit. Among other tests, a urine culture is performed showing 100 000 cfu/mL of E coli. The patient has no symptoms, and has not had pyelonephritis, dysuria, or fever. Which of the following is best next step for this patient?",
      "unique_key": "Q1346154",
      "question_audio": null,
      "question_video": null,
      "map_id": 34653521,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) This patient has asymptomatic bacteriuria, which should be treated even without symptoms. If untreated, the patient has a 25% risk of developing pyelonephritis during the pregnancy. Asymptomatic bacteriuria (ASB) complicates approximately 8% to 10% of pregnant patients. Providing treatment of ASB at the fi rst prenatal visit reduces the risk of pyelonephritis markedly. The choice of antibiotics for urinary tract infections (UTIs) during pregnancy must be safe for both the mother and the developing fetus. 1. Amoxicillin – A penicillin antibiotic that is commonly used and considered safe in pregnancy. 2. Cephalexin – A first-generation cephalosporin, also considered safe and effective for treating UTIs during pregnancy. 3. Nitrofurantoin – Often used for uncomplicated UTIs, but should be avoided in the later stages of pregnancy (third trimester) due to potential risks to the fetus. 4. Fosfomycin – A single-dose treatment that is safe during pregnancy and effective for uncomplicated UTIs. Note: Trimethoprim-sulfamethoxazole (TMP-SMX), tetracyclines, and quinolones are generally avoided during pregnancy because they may have harmful effects on the fetus.",
      "correct_choice_id": 236394,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75110661697031701/75110661697031701.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/75110661697031701/75110661697031701.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90882,
      "choices": [
        {
          "id": 236396,
          "text": "Ultrasound scan"
        },
        {
          "id": 236397,
          "text": "Combined test"
        },
        {
          "id": 236398,
          "text": "Serum screening (quadruple test)"
        },
        {
          "id": 236399,
          "text": "Chorionic villus sampling"
        }
      ],
      "text": "A 38 year old woman books at 17 weeks and requests screening for Down’s syndrome. Which of the following tests would be suitable for Down’s syndrome screening?",
      "unique_key": "Q8510218",
      "question_audio": null,
      "question_video": null,
      "map_id": 34047628,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Screening for Downs syndrome: The “combined test” (nuchal translucency, beta-human chorionic gonadotrophin pregnancy-associated plasma protein-A) should be ordered to all women to screen for Down’s syndrome between 11 weeks+ 0 days and 13 weeks and 6 days. For women who book after these dates, serum screening (triple or quadruple test) should be ordered between 15 weeks + 0 days and 20 weeks + 0 days. The components of the quadruple test are: 1. Alpha-fetoprotein (AFP) – A protein produced by the fetus. Low levels of AFP can indicate Down syndrome. 2. Human chorionic gonadotropin (hCG) – A hormone produced by the placenta. High levels of hCG can be associated with an increased risk of Down syndrome. 3. Unconjugated estriol (uE3) – A hormone produced by both the placenta and the fetus. Low levels of uE3 can indicate an increased risk of Down syndrome. 4. Inhibin A – A hormone produced by the placenta. Elevated levels of inhibin A can be associated with an increased risk of Down syndrome. The quadruple test is typically performed between the 15th and 20th weeks of pregnancy. It is used to assess the risk of Down syndrome, as well as other chromosomal abnormalities such as trisomy 18. The test is a screening tool, not a diagnostic test, meaning that if the results suggest a high risk, further diagnostic tests like amniocentesis should be recommended for confirmation.",
      "correct_choice_id": 236398,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/59785861697031721/59785861697031721.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/59785861697031721/59785861697031721.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90883,
      "choices": [
        {
          "id": 236400,
          "text": "Amniocentesis"
        },
        {
          "id": 236401,
          "text": "Cordocentesis"
        },
        {
          "id": 236402,
          "text": "Chorionic villus sampling (CVS)"
        },
        {
          "id": 236403,
          "text": "Doppler flow ultrasound"
        }
      ],
      "text": "A 41-year-old had a baby with Down syndrome 10 years ago. She is anxious to know the chromosome status of her fetus in a current pregnancy. The test that has the fastest lab processing time for karyotype is",
      "unique_key": "Q6411785",
      "question_audio": null,
      "question_video": null,
      "map_id": 34910733,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Chorionic villus sampling (CVS). Chorionic villus sampling is a prenatal test that involves taking a small sample of tissue from the placenta, which contains fetal cells. The advantage of CVS over other tests is that it can be performed as early as the 10th to 13th week of pregnancy and provides faster results for chromosomal analysis. The tissue sample collected to examine the karyotype of the fetus, typically yielding results within 72 hrs , making it the fastest option for karyotype analysis. Option A, amniocentesis, is a diagnostic test in which amniotic fluid is sampled to examine fetal cells. It is typically performed after the 15th week of pregnancy. While amniocentesis is reliable for detecting chromosomal abnormalities, it takes longer to process the results (usually 2-3 weeks), so it is not the fastest method for obtaining karyotype information. Option B, cordocentesis, also known as percutaneous umbilical blood sampling, involves taking a sample of fetal blood from the umbilical cord. It is typically performed after the 18th week of pregnancy and is generally used when other tests, such as amniocentesis or CVS, are inconclusive. However, cordocentesis carries higher risks compared to CVS and is typically not used for routine chromosomal analysis unless necessary. Results can also take about 2-3 weeks to process. Option D, Doppler flow ultrasound, is a non-invasive imaging technique used to measure blood flow in fetal vessels. It is not a diagnostic test for chromosomal abnormalities and does not provide any information about the karyotype of the fetus. Therefore, it is not relevant for determining the chromosome status in this scenario.",
      "correct_choice_id": 236402,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20317201697031752/20317201697031752.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/20317201697031752/20317201697031752.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90884,
      "choices": [
        {
          "id": 236404,
          "text": "Double bubble-duodenal atresia"
        },
        {
          "id": 236405,
          "text": "A membrane-covered mass protruding through the abdominal wall"
        },
        {
          "id": 236406,
          "text": "Fetal bowel floating around in the amniotic fluid"
        },
        {
          "id": 236407,
          "text": "Lack of a fetal skull"
        }
      ],
      "text": "Which of the following findings seen on ultrasound would NOT be an explanation for the elevated MSAFP?",
      "unique_key": "Q1244285",
      "question_audio": null,
      "question_video": null,
      "map_id": 34174708,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Duodenal atresia. Duodenal atresia is a congenital condition where there is a blockage or absence of the duodenum, the first part of the small intestine. While this condition is associated with other anomalies like Down syndrome, it does not directly contribute to an elevated maternal serum AFP. Elevated AFP levels are typically associated with defects that cause leakage of fetal material into the amniotic fluid, such as neural tube defects or abdominal wall defects. Duodenal atresia does not involve such leakage, making it an unlikely explanation for elevated maternal AFP levels. Option B, membrane covered mass through the abdominal wall, would likely be associated with gastroschisis or omphalocele. These conditions involve abdominal wall defects where fetal organs, such as the intestines, protrude through the abdominal wall. The presence of a membrane-covered mass could lead to elevated AFP levels, as the fetal tissue is exposed to the amniotic fluid, contributing to the higher AFP levels in the mother’s bloodstream. Option C, fetal bowel floating in amniotic fluid, is a classic sign of gastroschisis, a condition where the fetal intestines are exposed outside the body due to a hole in the abdominal wall. This condition is known to cause elevated maternal serum AFP, as the exposed fetal tissue leaks AFP into the amniotic fluid, raising the AFP levels in the maternal bloodstream. Option D, lack of fetal skull, is indicative of anencephaly, a severe neural tube defect where the fetal brain and skull do not fully develop. This condition leads to significantly elevated maternal serum AFP levels because of the leakage of fetal neural tissue into the amniotic fluid. The absence of the fetal skull can result in very high AFP levels.",
      "correct_choice_id": 236404,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51362731697031777/51362731697031777.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/51362731697031777/51362731697031777.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90885,
      "choices": [
        {
          "id": 236408,
          "text": "A4 B3 C2 D1"
        },
        {
          "id": 236409,
          "text": "A3 B4 C2 D1"
        },
        {
          "id": 236410,
          "text": "A1 B2 C3 D4"
        },
        {
          "id": 236411,
          "text": "A1 B3 C2 D4"
        }
      ],
      "text": "MATCH THE IMAGE SWITH CORRECT DIAGNOSIS<p><img src=\"https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/18(101).jpg\" alt=\"Question Image\"></p>",
      "unique_key": "Q7099558",
      "question_audio": null,
      "question_video": null,
      "map_id": 34318057,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) The sonographic image A shows two orbits, a mouth, and a central nose, but there is clearly no forehead and no cranial contents.. Anencephaly is, of course, incompatible with life and is the only condition for which a termination of pregnancy is generally permissible at any gestational age. The sonographic image 4 shows with a large nuchal translucency (double arrows) and beginning hydrops, sometimes called a cystic hygroma. Increasing experience with early sonograms has demonstrated that cystic hygromas occur in 1% to 2% of patients. In the second and third trimesters, cystic hygromas are commonly associated with Turner syndrome (45, X). The earlier in pregnancy they are seen, however, the more likely it is that the diagnosis is related to trisomy 21, trisomy 18, or trisomy 13, which are collectively found on karyotype in approximately 50% of cases. Of those cases that are chromosomally normal, most of these nuchal translucencies disappear and the fetus goes on to have perfectly normal development. The longitudinal sonographic image 3 shows the double bubble sign indicating duodenal atresia. The two bubbles are the stomach and the jejunum. This ?nding is classic for trisomy 21. Approximately one-third of fetuses who have this ?nding will be found to have trisomy 21. This risk is very high and is an automatic indication for o?ering prenatal diagnosis by amniocentesis, CVS, or cordocentesis to document the chromosomes regardless of any other indication the patient may have the ultrasound 2 shows splaying of the lumbar spine consistent with spina bifida",
      "correct_choice_id": 236408,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13476441697031815/13476441697031815.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/13476441697031815/13476441697031815.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90886,
      "choices": [
        {
          "id": 236412,
          "text": "Aneuploidy"
        },
        {
          "id": 236413,
          "text": "Duodenal atresia"
        },
        {
          "id": 236414,
          "text": "Cleft palate"
        },
        {
          "id": 236415,
          "text": "Cardiac defects"
        }
      ],
      "text": "41 year old G3P2 presents at 12 weeks for a first trimester sonographic evaluation. The following image is seen, following which she undergoes CVS and the fetal karyotype is 46 XY. Her fetus still needs to be evaluated in the second trimester for which of the following.<p><img src=\"https://d2enu63wt1sf3u.cloudfront.net/ckfinder/files/32(48).jpg\" alt=\"Question Image\"></p>",
      "unique_key": "Q1060452",
      "question_audio": null,
      "question_video": null,
      "map_id": 34740143,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) This image shows increased nuchal translucency, values more than/= 3mm is the cut off used. Increased NT is associated with aneuploidy in first trimester for which follow up was done with CVS which comes out as normal karyotype. The ideal time to measure it is between 11-13+6 days Increased NT is also associated with increased risk of structural anomalies particularly cardiac anomalies . this patient will definitely need evaluation of cardiovascular malformations in second trimester and both a fetal anantomic survey as well as fetal echocardiography both between 18-22 weeks must be done .",
      "correct_choice_id": 236415,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/60959381697031834/60959381697031834.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/60959381697031834/60959381697031834.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90887,
      "choices": [
        {
          "id": 236416,
          "text": "AFP"
        },
        {
          "id": 236417,
          "text": "Estradiol"
        },
        {
          "id": 236418,
          "text": "Hcg"
        },
        {
          "id": 236419,
          "text": "Inhibin B"
        }
      ],
      "text": "Which of this is not used in quadruple test",
      "unique_key": "Q1959693",
      "question_audio": null,
      "question_video": null,
      "map_id": 34453557,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Inhibin B The quadruple test (also called the quad screen) is a maternal blood test used during the second trimester of pregnancy to assess the risk of certain fetal conditions, including Down syndrome and neural tube defects. The test measures four substances in the mother’s blood: • Alpha-fetoprotein (AFP) • Human chorionic gonadotropin (hCG) • Estriol (a form of estrogen) • Inhibin A (not Inhibin B) Inhibin B is not included in the quadruple test. Instead, Inhibin A is measured as part of the test. Inhibin A levels are higher in pregnancies affected by Down syndrome, making it a useful marker in combination with the other substances measured in the test.",
      "correct_choice_id": 236419,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90888,
      "choices": [
        {
          "id": 236420,
          "text": "Twin pregnancy"
        },
        {
          "id": 236421,
          "text": "Down syndrome"
        },
        {
          "id": 236422,
          "text": "Ectopic pregnancy"
        },
        {
          "id": 236423,
          "text": "Choriocarcinoma"
        }
      ],
      "text": "High level of hCG is not seen in",
      "unique_key": "Q6480656",
      "question_audio": null,
      "question_video": null,
      "map_id": 34958167,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Ectopic pregnancy In an ectopic pregnancy, where the fertilized egg implants outside the uterus (typically in the fallopian tube), hCG levels may be elevated, but they are typically lower and rise more slowly than in a normal intrauterine pregnancy. This is because the production of hCG in an ectopic pregnancy is less efficient due to the abnormal implantation site. Unlike a normal pregnancy, where hCG levels double approximately every 48-72 hours, in ectopic pregnancy, this pattern may not be observed, leading to a slower rise or lower peak in hCG levels. As a result, high levels of hCG are not typically seen in ectopic pregnancies.",
      "correct_choice_id": 236422,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90889,
      "choices": [
        {
          "id": 236424,
          "text": "Done at 16 weeks"
        },
        {
          "id": 236425,
          "text": "Done for chromosomal abnormality"
        },
        {
          "id": 236426,
          "text": "Increased NT is an indication for CVS"
        },
        {
          "id": 236427,
          "text": "Trophoblastic cells are tested"
        }
      ],
      "text": "False about Chorionic villus sampling",
      "unique_key": "Q5273295",
      "question_audio": null,
      "question_video": null,
      "map_id": 34667082,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Done at 16 weeks This statement is false because chorionic villus sampling (CVS) is typically performed between 10 and 13 weeks of gestation, not at 16 weeks. CVS is an early prenatal diagnostic test that involves sampling a small portion of placental tissue (chorionic villi) to analyze fetal chromosomes. Performing CVS beyond 13 weeks increases the risk of complications and does not provide any diagnostic advantage over amniocentesis, which is preferred after 15 weeks. Therefore, saying that CVS is done at 16 weeks is incorrect and does not reflect current clinical guidelines.",
      "correct_choice_id": 236424,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90890,
      "choices": [
        {
          "id": 236428,
          "text": "Alpha-fetoprotein"
        },
        {
          "id": 236429,
          "text": "Unconjugated estriol"
        },
        {
          "id": 236430,
          "text": "PAPPA"
        },
        {
          "id": 236431,
          "text": "Inhibin A"
        }
      ],
      "text": "Which of the following biochemical markers is uniquely increased in maternal serum in pregnancies affected by Down syndrome?",
      "unique_key": "Q9172933",
      "question_audio": null,
      "question_video": null,
      "map_id": 34894845,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Inhibin A Inhibin A is a glycoprotein hormone produced by the placenta, and its levels are uniquely elevated in maternal serum in pregnancies affected by Down syndrome (trisomy 21), particularly in the second trimester. It is a key component of the quadruple screening test, which is typically performed between 15–20 weeks of gestation. In cases of Down syndrome, inhibin A levels are significantly increased, making it a distinguishing biochemical marker when compared to other conditions or chromosomal abnormalities. The inclusion of inhibin A improves the sensitivity and specificity of Down syndrome screening when combined with other markers.",
      "correct_choice_id": 236431,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90891,
      "choices": [
        {
          "id": 236432,
          "text": "NIPT is based on the analysis of fetal nucleated red blood cells in maternal circulation"
        },
        {
          "id": 236433,
          "text": "NIPT has a lower sensitivity and specificity compared to first-trimester combined screening"
        },
        {
          "id": 236434,
          "text": "NIPT can be performed as early as 9-10 weeks of gestation"
        },
        {
          "id": 236435,
          "text": "A positive NIPT result confirm the diagnosis of Down syndrome"
        }
      ],
      "text": "Which of the following statements regarding Non-Invasive Prenatal Testing (NIPT) for Down syndrome is TRUE?",
      "unique_key": "Q2644173",
      "question_audio": null,
      "question_video": null,
      "map_id": 34029649,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) NIPT can be performed as early as 9-10 weeks of gestation Non-Invasive Prenatal Testing (NIPT) is a highly sensitive screening method that analyzes cell-free fetal DNA (cffDNA) circulating in the maternal blood. This DNA originates from placental trophoblasts and becomes detectable in the maternal circulation by around 9–10 weeks of gestation, making this the earliest reliable time for testing. NIPT offers a non-invasive, early, and safe option for screening for common chromosomal aneuploidies such as trisomy 21 (Down syndrome), trisomy 18, and trisomy 13. Because of its high sensitivity (>99%) and specificity for Down syndrome, NIPT is considered superior to traditional serum screening methods, especially for women at higher risk.",
      "correct_choice_id": 236434,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90892,
      "choices": [
        {
          "id": 236436,
          "text": "Blood grouping and Rh typing"
        },
        {
          "id": 236437,
          "text": "Diabetes screening"
        },
        {
          "id": 236438,
          "text": "Measurement of nuchal translucency"
        },
        {
          "id": 236439,
          "text": "HIV test"
        }
      ],
      "text": "Which of the following is NOT a routine component of the first antenatal visit",
      "unique_key": "Q3011973",
      "question_audio": null,
      "question_video": null,
      "map_id": 34546324,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Measurement of nuchal translucency Nuchal translucency (NT) measurement is not a routine component of the first antenatal visit, which typically occurs around 6–10 weeks of gestation. NT is a specialized ultrasound screening test done between 11 and 14 weeks of gestation to assess the risk of chromosomal abnormalities, such as Down syndrome (trisomy 21). Because it requires a certain gestational age window for accuracy and utility, it is not performed during the initial antenatal visit. Rather, it is part of the first trimester combined screening, which may include NT measurement along with serum markers (free ?-hCG and PAPP-A) done slightly later in early pregnancy",
      "correct_choice_id": 236438,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90893,
      "choices": [
        {
          "id": 236440,
          "text": "Shortened femur length"
        },
        {
          "id": 236441,
          "text": "Increased nuchal translucency (NT) > 3mm"
        },
        {
          "id": 236442,
          "text": "Absent nasal bone"
        },
        {
          "id": 236443,
          "text": "Echogenic intracardiac focus"
        }
      ],
      "text": "Which of the following sonographic markers is considered the most sensitive first-trimester ultrasound finding suggestive of Down syndrome?",
      "unique_key": "Q2087866",
      "question_audio": null,
      "question_video": null,
      "map_id": 34209864,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Increased nuchal translucency (NT) > 3 Increased nuchal translucency (NT) > 3 mm is considered the most sensitive first-trimester ultrasound marker for Down syndrome. Nuchal translucency refers to the fluid-filled space at the back of the fetal neck. An increased NT measurement is a strong indication of chromosomal abnormalities, including Down syndrome (trisomy 21), and is often one of the first markers seen on ultrasound during the first trimester (typically between 11-14 weeks of gestation). An NT measurement greater than 3 mm is highly suggestive of an increased risk of Down syndrome, and it warrants further diagnostic testing like NIPT or amniocentesis",
      "correct_choice_id": 236441,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90894,
      "choices": [
        {
          "id": 236444,
          "text": "Paternal DNA in maternal serum"
        },
        {
          "id": 236445,
          "text": "Fetal DNA from chorionic villi in the placenta"
        },
        {
          "id": 236446,
          "text": "Fetal DNA from placental trophoblasts in maternal blood"
        },
        {
          "id": 236447,
          "text": "Maternal DNA in the amniotic fluid"
        }
      ],
      "text": "Non-invasive prenatal testing (NIPT) detects Down syndrome by analyzing which type of DNA?",
      "unique_key": "Q7575036",
      "question_audio": null,
      "question_video": null,
      "map_id": 34225463,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Fetal DNA from placental trophoblasts in maternal blood Non-invasive prenatal testing (NIPT) detects fetal DNA circulating in the maternal blood. This DNA comes from the placental trophoblasts, which are the cells that make up the placenta. These trophoblasts shed small amounts of cell-free fetal DNA (cfDNA) into the maternal bloodstream. NIPT analyzes this fetal DNA to detect chromosomal abnormalities like Down syndrome (trisomy 21), trisomy 18, and trisomy 13, with very high accuracy. It is a non-invasive, highly sensitive test that can be performed as early as 9-10 weeks gestation",
      "correct_choice_id": 236446,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90895,
      "choices": [
        {
          "id": 236448,
          "text": "Low AFP, high β-hCG, low uE3, high inhibin-A"
        },
        {
          "id": 236449,
          "text": "High AFP, low β-hCG, high uE3, low inhibin-A"
        },
        {
          "id": 236450,
          "text": "High AFP, high β-hCG, high uE3, low inhibin-A"
        },
        {
          "id": 236451,
          "text": "Low AFP, low β-hCG, high uE3, low inhibin-A"
        }
      ],
      "text": "In Down syndrome, what is the usual pattern of maternal serum markers in the second-trimester quadruple test?",
      "unique_key": "Q7596371",
      "question_audio": null,
      "question_video": null,
      "map_id": 34994222,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Low AFP, high ?-hCG, low uE3, high inhibin-A In the second-trimester quadruple test for Down syndrome, the typical pattern of maternal serum markers is as follows: • Low AFP (alpha-fetoprotein): AFP is typically lower in pregnancies with Down syndrome. • High ?-hCG (beta-human chorionic gonadotropin): ?-hCG levels are elevated in pregnancies affected by Down syndrome, due to increased placental production. • Low uE3 (unconjugated estriol): Estriol is typically lower in Down syndrome pregnancies, reflecting impaired fetal development. • High inhibin-A: Inhibin-A levels are higher in Down syndrome, as the placenta produces more of this hormone in trisomic pregnancies. This combination of markers—low AFP, high ?-hCG, low uE3, and high inhibin-A—is a characteristic finding in the second-trimester quadruple test for Down syndrome",
      "correct_choice_id": 236448,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90896,
      "choices": [
        {
          "id": 236452,
          "text": "Combined test"
        },
        {
          "id": 236453,
          "text": "NIPT"
        },
        {
          "id": 236454,
          "text": "Quadruple test"
        },
        {
          "id": 236455,
          "text": "Serum integrated test"
        }
      ],
      "text": "Which of the following screening tests has the highest detection rate for Down syndrome?",
      "unique_key": "Q1963542",
      "question_audio": null,
      "question_video": null,
      "map_id": 34045036,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) NIPT Non-Invasive Prenatal Testing (NIPT) is currently the most accurate screening test for Down syndrome and other chromosomal abnormalities. NIPT analyzes cell-free fetal DNA circulating in the mother's blood, which allows for highly accurate detection of trisomy 21 (Down syndrome), trisomy 18, and trisomy 13. The detection rate for Down syndrome is typically over 99% with a very low false-positive rate. NIPT can be done as early as 10 weeks gestation and is non-invasive, making it an ideal choice for women at higher risk or those who want a more definitive screening option.",
      "correct_choice_id": 236453,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 90897,
      "choices": [
        {
          "id": 236456,
          "text": "Quadruple test"
        },
        {
          "id": 236457,
          "text": "NIPT"
        },
        {
          "id": 236458,
          "text": "Combined test"
        },
        {
          "id": 236459,
          "text": "Chorionic villus sampling"
        }
      ],
      "text": "Which of the following is the most commonly used first-trimester screening test for Down syndrome?",
      "unique_key": "Q8668111",
      "question_audio": null,
      "question_video": null,
      "map_id": 34283503,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Combined The Combined Test is the most commonly used first-trimester screening method for Down syndrome (trisomy 21). It is typically performed between 11 and 13+6 weeks of gestation and combines: • Nuchal translucency measurement via ultrasound, • Serum free beta-hCG levels, and • Pregnancy-associated plasma protein-A (PAPP-A) levels. By evaluating both biochemical markers and an ultrasound finding, the combined test provides a high detection rate (around 85–90%) for Down syndrome with a relatively low false-positive rate. It is noninvasive and helps stratify risk early enough to offer further diagnostic testing if needed, such as chorionic villus sampling or amniocentesis.",
      "correct_choice_id": 236458,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    }
  ]
}